Pharnext is an advanced clinical stage biopharmaceutical company developing new therapeutics that simultaneously target multiple key disease pathways for severe orphan and common neurological diseases. The proprietary R&D platform of Pharnext is based on network pharmacology. It allows the development of synergistic combinations of repositioned drugs – pleodrugs – which benefit from an outstanding safety profile and IP with strong enforceability. The company’s two lead pleodrugs are PXT3003 for the treatment of Charcot-Marie-Tooth disease type 1A (Phase 3 ongoing) and PXT864 for Alzheimer’s disease (Phase 2a ongoing) and other neurologic indications (Parkinson’s disease, amyotrophic lateral sclerosis).
THE INTERNATIONAL PIVOTAL PHASE 3 STUDY OF PXT3003 FOR THE TREATMENT OF CHARCOT-MARIE-TOOTH DISEASE TYPE 1A IS ONGOING.
If you would like more information about this clinical trial, please visit the following websites:
For France: CMT France - http://www.cmt-france.org
For other European countries: OrphanDev - http://www.orphan-dev.org
For the US: Hereditary Neuropathy Foundation (HNF) - http://www.hnf-cure.org
Worldwide: ClinicalTrials - https://clinicaltrials.gov